21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia: The Great Pretender

Carlos Moran, Ricardo Azziz

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Polycystic ovary syndrome (PCOS) affects about 4 to 6% of women of reproductive age and accounts for at least 75% of hyperandrogenic patients. PCOS is diagnosed by the presence of oligo-ovulation and hyperandrogenism after the exclusion of related disorders, such as 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH). In turn, NCAH is a homozygous recessive disorder, diagnosed by a corticotropin-stimulated 17-hydroxyprogesterone (17-HP) level greater than 10 ng/mL (30.3 nmol/L) and confirmed by genotyping of the CYP21 gene. The prevalence of NCAH is approximately 50 times less than that of PCOS, affecting between 1 and 10% of hyperandrogenic women, depending on ethnicity. However, it is generally difficult to distinguish NCAH from PCOS solely on clinical grounds, as both demonstrate varying degrees of hyperandrogenism and ovulatory dysfunction. Most PCOS patients have insulin resistance, in contrast to those with NCAH. Likewise, polycystic ovaries are observed in up to 40% of NCAH patients. Both disorders have a strong familial component. The only method that allows the separation of NCAH from PCOS patients is the measurement of 17-HP levels. In conclusion, PCOS and NCAH have differences in prevalence and pathophysiology. However, because the disorders have significant clinical and hormonal similarities, the measurement of 17-HP, preferably basally as a screening method, should be incorporated into the evaluation of all hyperandrogenic patients.

Original languageEnglish (US)
Pages (from-to)295-300
Number of pages6
JournalSeminars in Reproductive Medicine
Volume21
Issue number3
DOIs
StatePublished - Aug 1 2003

Fingerprint

Steroid 21-Hydroxylase
Polycystic Ovary Syndrome
Hyperplasia
17-alpha-Hydroxyprogesterone
Hyperandrogenism
Ovulation
Adrenocorticotropic Hormone
Insulin Resistance
Ovary

Keywords

  • Adrenal hyperplasia
  • Hyperandrogenism
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Endocrinology
  • Obstetrics and Gynecology
  • Physiology (medical)

Cite this

21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia : The Great Pretender. / Moran, Carlos; Azziz, Ricardo.

In: Seminars in Reproductive Medicine, Vol. 21, No. 3, 01.08.2003, p. 295-300.

Research output: Contribution to journalReview article

Moran, Carlos ; Azziz, Ricardo. / 21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia : The Great Pretender. In: Seminars in Reproductive Medicine. 2003 ; Vol. 21, No. 3. pp. 295-300.
@article{c3df0acc233b4a4195c2a6e9b24c2ba7,
title = "21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia: The Great Pretender",
abstract = "Polycystic ovary syndrome (PCOS) affects about 4 to 6{\%} of women of reproductive age and accounts for at least 75{\%} of hyperandrogenic patients. PCOS is diagnosed by the presence of oligo-ovulation and hyperandrogenism after the exclusion of related disorders, such as 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH). In turn, NCAH is a homozygous recessive disorder, diagnosed by a corticotropin-stimulated 17-hydroxyprogesterone (17-HP) level greater than 10 ng/mL (30.3 nmol/L) and confirmed by genotyping of the CYP21 gene. The prevalence of NCAH is approximately 50 times less than that of PCOS, affecting between 1 and 10{\%} of hyperandrogenic women, depending on ethnicity. However, it is generally difficult to distinguish NCAH from PCOS solely on clinical grounds, as both demonstrate varying degrees of hyperandrogenism and ovulatory dysfunction. Most PCOS patients have insulin resistance, in contrast to those with NCAH. Likewise, polycystic ovaries are observed in up to 40{\%} of NCAH patients. Both disorders have a strong familial component. The only method that allows the separation of NCAH from PCOS patients is the measurement of 17-HP levels. In conclusion, PCOS and NCAH have differences in prevalence and pathophysiology. However, because the disorders have significant clinical and hormonal similarities, the measurement of 17-HP, preferably basally as a screening method, should be incorporated into the evaluation of all hyperandrogenic patients.",
keywords = "Adrenal hyperplasia, Hyperandrogenism, Polycystic ovary syndrome",
author = "Carlos Moran and Ricardo Azziz",
year = "2003",
month = "8",
day = "1",
doi = "10.1055/s-2003-43307",
language = "English (US)",
volume = "21",
pages = "295--300",
journal = "Seminars in Reproductive Medicine",
issn = "1526-8004",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - 21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia

T2 - The Great Pretender

AU - Moran, Carlos

AU - Azziz, Ricardo

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Polycystic ovary syndrome (PCOS) affects about 4 to 6% of women of reproductive age and accounts for at least 75% of hyperandrogenic patients. PCOS is diagnosed by the presence of oligo-ovulation and hyperandrogenism after the exclusion of related disorders, such as 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH). In turn, NCAH is a homozygous recessive disorder, diagnosed by a corticotropin-stimulated 17-hydroxyprogesterone (17-HP) level greater than 10 ng/mL (30.3 nmol/L) and confirmed by genotyping of the CYP21 gene. The prevalence of NCAH is approximately 50 times less than that of PCOS, affecting between 1 and 10% of hyperandrogenic women, depending on ethnicity. However, it is generally difficult to distinguish NCAH from PCOS solely on clinical grounds, as both demonstrate varying degrees of hyperandrogenism and ovulatory dysfunction. Most PCOS patients have insulin resistance, in contrast to those with NCAH. Likewise, polycystic ovaries are observed in up to 40% of NCAH patients. Both disorders have a strong familial component. The only method that allows the separation of NCAH from PCOS patients is the measurement of 17-HP levels. In conclusion, PCOS and NCAH have differences in prevalence and pathophysiology. However, because the disorders have significant clinical and hormonal similarities, the measurement of 17-HP, preferably basally as a screening method, should be incorporated into the evaluation of all hyperandrogenic patients.

AB - Polycystic ovary syndrome (PCOS) affects about 4 to 6% of women of reproductive age and accounts for at least 75% of hyperandrogenic patients. PCOS is diagnosed by the presence of oligo-ovulation and hyperandrogenism after the exclusion of related disorders, such as 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH). In turn, NCAH is a homozygous recessive disorder, diagnosed by a corticotropin-stimulated 17-hydroxyprogesterone (17-HP) level greater than 10 ng/mL (30.3 nmol/L) and confirmed by genotyping of the CYP21 gene. The prevalence of NCAH is approximately 50 times less than that of PCOS, affecting between 1 and 10% of hyperandrogenic women, depending on ethnicity. However, it is generally difficult to distinguish NCAH from PCOS solely on clinical grounds, as both demonstrate varying degrees of hyperandrogenism and ovulatory dysfunction. Most PCOS patients have insulin resistance, in contrast to those with NCAH. Likewise, polycystic ovaries are observed in up to 40% of NCAH patients. Both disorders have a strong familial component. The only method that allows the separation of NCAH from PCOS patients is the measurement of 17-HP levels. In conclusion, PCOS and NCAH have differences in prevalence and pathophysiology. However, because the disorders have significant clinical and hormonal similarities, the measurement of 17-HP, preferably basally as a screening method, should be incorporated into the evaluation of all hyperandrogenic patients.

KW - Adrenal hyperplasia

KW - Hyperandrogenism

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=0142062619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142062619&partnerID=8YFLogxK

U2 - 10.1055/s-2003-43307

DO - 10.1055/s-2003-43307

M3 - Review article

C2 - 14593552

AN - SCOPUS:0142062619

VL - 21

SP - 295

EP - 300

JO - Seminars in Reproductive Medicine

JF - Seminars in Reproductive Medicine

SN - 1526-8004

IS - 3

ER -